NHS Galleri trial misses its main goal on late-stage cancer reduction
TL;DR Summary
Results from the UK's largest randomized trial of the Galleri multi-cancer blood test showed no statistically significant reduction in late-stage cancers (stages 3–4) when added to standard screening; while a secondary look at stage-4 cancers suggested a 14% reduction, mortality outcomes are still pending.
- Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim The Guardian
- The $950 cancer blood test is here: 5 things to consider before ordering yours Business Insider
- Screening with a multi-cancer blood test reduced the most advanced cancers University of Exeter News
- Gilberto Lopes: NHS-Galleri - The First Randomized Trial of an MCED Test in 142,000+ NHS Participants Oncodaily
- GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting BioSpace
Reading Insights
Total Reads
0
Unique Readers
19
Time Saved
3 min
vs 4 min read
Condensed
93%
636 → 44 words
Want the full story? Read the original article
Read on The Guardian